The Association for Diagnostics and Laboratory Medicine (ADLM) 2026 is coming up, bringing together professionals across clinical chemistry, molecular diagnostics and laboratory management.
The event will host over 300 expert speakers and over 250 educational sessions.
Swiss biotechnology and healthcare company Roche will be attending this year’s ADLM to showcase its integrated diagnostic solutions. These solutions expand expand high-precision testing, automate laboratory workflows and improve operational efficiency.
The company plans to feature its new Axelio 1 next-generation sequencing platform. The aim is to make genomics research faster, more flexible and more affordable for laboratories.
It will also unveil the cobas Mass Spec solution, offering attendees an exclusive look at Roche’s approach to automated clinical mass spectrometry. The cobas Mass Spec solution is designed to bring highly complex testing out of specialised units and into routine clinical core laboratories. The solution integrates end-to-end processing and eliminates labour-intensive manual workflows.
Visitors can explore interactive demonstrations focused on neurology, oncology and cardiometabolic health, highlighting innovations across core, molecular and pathology labs and point-of-care settings.
The products featured at ADLM will display how intelligent automation, cloud-based workflow visibility and AI-enabled diagnostics can reduce manual touchpoints and alleviate labour shortages.
ADLM 2026 will take place 26th to 30th July at the Anaheim Convention Centre in California.
